Literature DB >> 22180675

Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear.

Peniel M Dimberu1, Ralf M Leonhardt.   

Abstract

Cancer accounts for about every fourth death in the United States, with approximately 1,500 people dying each day as a result of this disease. Despite some progress in the last decades, these numbers alone undoubtedly demonstrate the urgent need for new and more efficient treatments. Immunotherapy aims to activate an efficient immune response against tumors or even prevent cancers from occurring in the first place. It is a growing field currently flourishing with several successful trials, some of which have led to the recent approval of new anti-cancer drugs by the Food and Drug Administration (FDA). This review addresses the manifold strategies that immunotherapy has taken in the past and discusses the most recent achievements in the field.

Entities:  

Keywords:  cancer vaccine; immune response; immunotherapy; monoclonal antibody

Mesh:

Substances:

Year:  2011        PMID: 22180675      PMCID: PMC3238317     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  47 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

Review 2.  Antibody-targeted radiation cancer therapy.

Authors:  Diane E Milenic; Erik D Brady; Martin W Brechbiel
Journal:  Nat Rev Drug Discov       Date:  2004-06       Impact factor: 84.694

Review 3.  "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy.

Authors:  Federico Garrido; Teresa Cabrera; Natalia Aptsiauri
Journal:  Int J Cancer       Date:  2010-07-15       Impact factor: 7.396

Review 4.  Recent advances in cancer therapy: an overview.

Authors:  A Urruticoechea; R Alemany; J Balart; A Villanueva; F Viñals; G Capellá
Journal:  Curr Pharm Des       Date:  2010-01       Impact factor: 3.116

Review 5.  Current aspects of anti-CD20 therapy in rheumatoid arthritis.

Authors:  Annett M Jacobi; Thomas Dörner
Journal:  Curr Opin Pharmacol       Date:  2010-02-26       Impact factor: 5.547

Review 6.  Prophylactic human papillomavirus vaccines.

Authors:  Douglas R Lowy; John T Schiller
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

7.  Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines.

Authors:  Franz O Smith; Stephanie G Downey; Jacob A Klapper; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Nicholas P Restifo; Catherine L Levy; Donald E White; Seth M Steinberg; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

8.  Molecular architecture of the TAP-associated MHC class I peptide-loading complex.

Authors:  Elke Rufer; Ralf M Leonhardt; Michael R Knittler
Journal:  J Immunol       Date:  2007-11-01       Impact factor: 5.422

9.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

Review 10.  Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma.

Authors:  Fabio Grizzi; Barbara Franceschini; Cody Hamrick; Eldo E Frezza; Everardo Cobos; Maurizio Chiriva-Internati
Journal:  J Transl Med       Date:  2007-01-23       Impact factor: 5.531

View more
  20 in total

Review 1.  Monoclonal antibodies in cancer immunotherapy.

Authors:  Ilgin Kimiz-Gebologlu; Sultan Gulce-Iz; Cigir Biray-Avci
Journal:  Mol Biol Rep       Date:  2018-10-11       Impact factor: 2.316

2.  Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen.

Authors:  Nathalie Vigneron; Violette Ferrari; Benoît J Van den Eynde; Peter Cresswell; Ralf M Leonhardt
Journal:  J Immunol       Date:  2018-08-22       Impact factor: 5.422

Review 3.  Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity.

Authors:  Jiu-Cheng Zhang; Wei-Dong Chen; Jean Bustamante Alvarez; Kelly Jia; Lei Shi; Qiang Wang; Ning Zou; Kai He; Hua Zhu
Journal:  Acta Pharmacol Sin       Date:  2018-07-10       Impact factor: 6.150

4.  Three tapasin docking sites in TAP cooperate to facilitate transporter stabilization and heterodimerization.

Authors:  Ralf M Leonhardt; Parwiz Abrahimi; Susan M Mitchell; Peter Cresswell
Journal:  J Immunol       Date:  2014-02-05       Impact factor: 5.422

Review 5.  Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy.

Authors:  Maureen L Drakes; Patrick J Stiff
Journal:  Immunotargets Ther       Date:  2014-12-04

6.  Cytotoxic T cells response with decreased CD4/CD8 ratio during mammary tumors inhibition in rats induced by non-contact electric fields.

Authors:  Firman Alamsyah; Rarastoeti Pratiwi; Nisrina Firdausi; Jessica Irene Mesak Pello; Subekti Evi Dwi Nugraheni; Ahmad Ghitha Fadhlurrahman; Luthfi Nurhidayat; Warsito Purwo Taruno
Journal:  F1000Res       Date:  2021-01-19

7.  Critical residues in the PMEL/Pmel17 N-terminus direct the hierarchical assembly of melanosomal fibrils.

Authors:  Ralf M Leonhardt; Nathalie Vigneron; Jia Shee Hee; Morven Graham; Peter Cresswell
Journal:  Mol Biol Cell       Date:  2013-02-06       Impact factor: 4.138

8.  Gemcitabine hydrochloride-loaded functionalised carbon nanotubes as potential carriers for tumour targeting.

Authors:  Shilpee Das; Jagruti L Desai; Hetal P Thakkar
Journal:  Indian J Pharm Sci       Date:  2013-11       Impact factor: 0.975

9.  Antitumor Effect of IP-10 by Using Two Different Approaches: Live Delivery System and Gene Therapy.

Authors:  Yasaman Taslimi; Farnaz Zahedifard; Sima Habibzadeh; Tahereh Taheri; Hossain Abbaspour; Alireza Sadeghipour; Elham Mohit; Sima Rafati
Journal:  J Breast Cancer       Date:  2016-03-25       Impact factor: 3.588

10.  A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors.

Authors:  Catherine Gérard; Nathalie Baudson; Thierry Ory; Lawrence Segal; Jamila Louahed
Journal:  J Immunother       Date:  2015-10       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.